Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicity.

ABSTRACT:

Background

The neoantigen vaccine has remarkable potential in treating advanced cancer due to its tumor specificity and ability to bypass central tolerance mechanisms. However, numerous neoantigens show poor immunogenicity, and the immune inhibitory factors of present in both tumors and tumor-draining lymph nodes impair the efficacy of cancer neoantigen vaccine. Eliminating immunosuppressive cells will improve the priming and expansion of anti-tumor immune cells induced by the vaccine.

Methods

In this study, a Treg-depleting regimen (consisting of CD25mAb and low-dose cyclophosphamide (LD-CTX)) was used in conjunction with a neoantigen vaccine for treating mice with solid tumors. We constructed two types of tumor models and investigated differences in therapy efficacy in the

SUBMITTER: Huang R 

PROVIDER: S-EPMC11625159 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature